Pharma Marketletter

View more issues:

Articles in January, 2003 issue of Pharma Marketletter

• 53.7% US sales leap boosts Sanofi-Synthelabo.
• HIV/AIDS Rx access initiative sees prices drop 85%-90%, calls for more resources.
• Stock Commentary - week to Jan 20 - Europe.
• Dragon updates business strategy.
• Japanese pharma to grow 23% in next five years fueled by overseas launches.
• UK NICE revises advice on B-MS' Taxol.
• GSK "in negotiation" with Canadian Internet drug suppliers as deadline passes.
• Global Rx sales up 7% in 12 months to Nov O02.
• Abbott's profits up 2%, forecasts lowered.
• RiboTargets confirms it is in merger talks with British Biotech.
• Major French health reforms due in third quarter.
• Pfizer posts 46% rise in 4th qtr earnings on 14% higher blockbuster drug sales.
• UK MCA needs to raise its public profile, address quality of info and advice: govt.
• Profits up at J&J in fourth quarter as lead drugs and devices perform well.
• Effect of Merck & Co Banyu buy assessed.
• China's govt focusing R&D to foster growth of new pharma industry.
• Ranbaxy 4th-qtr net profit rockets 323%.
• Novartis to rebrand generics under single global name: Sandoz.
• UK's ReNeuron hit by pain drug's failure in Phase II study.
• Australian doctors warn over generics move.
• Tokyo pharma stocks - week to Jan 20.
• US states form non-profit PBM to curb Medicaid, state employee Rx plan costs.
• Update - Amgen says Enbrel psoriasis trial is positive.
• US doctors positive over DTC, but see need to provide additional info: FDA study.
• EU unequal drug access "needs public debate".
• Boston Sci gets Euro OK for paclitaxel stent.
• Stock Commentary - week to Jan 20 - New York.